Yersinia pestis infection future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:
==Overview==
==Overview==


<!--


Research is under way to develop improved plague vaccines that are likely to be protective against airborne infection and could be administered as inhalants.66,67 At present, the most promising candidates are recombi- nant subunit vaccines that express F1 and V antigens of Y. pestis and seem to protect animals against infective aerosol exposures.68-70 A wide variety of other approaches are also under investigation, including passive immunization with aerosolized monoclonal antibodies71 and vaccines based on attenuated Y. pseudotuberculosis.72,73
==Future and Investigational Therapies==
Research studies are under way to improve the plague vaccine. The qualities searched in the new vaccine include:
* Protection from airborne infection
* Inhaled administration
 
A current potential vaccine is a recombinant type, expressing both V and F1 antigens of Yersinia pestis. This vaccine appears to protect animals against this type of infection as well. Other options include:
* Aerosolized monoclonal antibodies
* Attenuated form of [[Yersinia pseudotuberculosis]]


-->
==References==
==References==



Revision as of 19:29, 25 July 2014

Yersinia pestis infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Yersinia Pestis Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Yersinia pestis infection future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Yersinia pestis infection future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Yersinia pestis infection future or investigational therapies

CDC on Yersinia pestis infection future or investigational therapies

Yersinia pestis infection future or investigational therapies in the news

Blogs on Yersinia pestis infection future or investigational therapies

Directions to Hospitals Treating Yersinia pestis infection

Risk calculators and risk factors for Yersinia pestis infection future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Future and Investigational Therapies

Research studies are under way to improve the plague vaccine. The qualities searched in the new vaccine include:

  • Protection from airborne infection
  • Inhaled administration

A current potential vaccine is a recombinant type, expressing both V and F1 antigens of Yersinia pestis. This vaccine appears to protect animals against this type of infection as well. Other options include:

References

Template:WikiDoc Sources